Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma

NCT04546074 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Pembrolizumab and Imatinib mesylate
DRUG: Pembrolizumab and Imatinib mesylate

Sponsor

Keio University

Collaborators

[object Object]
[object Object]